Difference between revisions of "Citalopram-hypericum"

From Psychiatrienet
Jump to: navigation, search
Line 8: Line 8:
 
| caveat =  
 
| caveat =  
 
* Occurrence of the serotonin syndrome is possible without wash-out period.
 
* Occurrence of the serotonin syndrome is possible without wash-out period.
 +
{{Lit-SSRI-Hypericum}}
 
| info = {{HypericumInfo}}
 
| info = {{HypericumInfo}}
 
}}
 
}}

Revision as of 14:46, 12 March 2010

Citalopram
Type Antidepressant
Group SSRI
links
ATC-code N06AB04
Medscape Citalopram
PubChem 2771
PubMed Citalopram
Kompas (Dutch) citalopram
Wikipedia citalopram
Hypericum
Type Antidepressant
Group other
links
EMEA 10130408en
PubMed Hypericum
Kompas (Dutch) hypericum extract
Wikipedia St John's wort

Switch medication from citalopram to hypericum.[1] [2]

Nietinrijdenbord.png Stop citalopram
  • Before day 1: gradually reduce dosage of citalopram to a maximum of 20 mg/day, when this dosage is > 20 mg/day.
  • Day 1: reduce dosage of citalopram to a maximum of 10 mg/day.
  • Day 8: stop administration of citalopram
Eenrichtingbord.png Start hypericum
  • Day 8-22: a wash-out period of 2 weeks is necessary.
  • Day 23: start administration of hypericum in a dosage of 300 mg three times a day (900 mg/day).
Letopbord.png Cave
  • Occurrence of the serotonin syndrome is possible without wash-out period.

[3]

Infobord.png More information
  • Hypericum induces enzymes of the CYP P-450 type and P-gp type.
  • Hypericum might have MAO-inhibiting and/or COMT-inhibiting properties.
  • Many studies reported that hypericin is the main source of pharmacological effects of hypericum. However the IC50 of hypericin to inhibit MAO A and MAO B is 100- to 1000-fold higher than accessible Cmax values of hypericin after oral administration of hypericum.[4]
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
  3. F. Borelli et al.Herb-drug interactions with St John's wort (Hypericum perforatum): an update on clinical observations. AAPS J. 2009 Dec;11(4):710-27
  4. Wurglics M, Schubert-Zsilavecz M.Hypericum perforatum: a 'modern' herbal antidepressant: pharmacokinetics of active ingredients. Clin Pharmacokinet. 2006;45(5):449-68.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.